| Name | Value |
|---|---|
| Revenues | 1,835.0K |
| Cost of Revenue | 1,432.0K |
| Gross Profit | 403.0K |
| Operating Expense | 3,606.0K |
| Operating I/L | -3,203.0K |
| Other Income/Expense | 302.0K |
| Interest Income | 400.0K |
| Pretax | -2,901.0K |
| Income Tax Expense | -702.0K |
| Net Income/Loss | -2,199.0K |
Perspective Therapeutics, Inc. develops, manufactures, and markets isotope-based medical products and devices for cancer treatment. Its flagship product, CS-1 Cesium-131 brachytherapy seeds, is used for various cancer types including prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. The company generates revenue by selling these products to facilities and physician practices that utilize surgical facilities for cancer treatment.